Ophthalmic Startup Gets $5 Million Investment To Complete Phase 2 Clinical Trials
FARMINGTON HILLS—Ocuphire Pharma Inc., a clinical-stage pharmaceutical company developing therapies to treat patients with a variety of ophthalmic disorders, announced that it has closed on over $5 million of financing. Investors include Jackson-based RBI Opportunities Fund, Douglas, Mich.-based Belle Capital Fund, Grand Rapids-based Grand Angels Fund, Farmington Hills-based First Capital Fund, Ann Arbor-based Michigan Angel